AMPK activation by AICAR sensitizes prostate cancer cells to radiotherapy
Metrics: PDF 218 views | HTML 401 views | ?
Colin Rae1 and Robert J. Mairs1
1Radiation Oncology, Institute of Cancer Sciences, University of Glasgow, Glasgow, UK
Colin Rae, email: Colin.Rae@glasgow.ac.uk
Keywords: prostate cancer; radiosensitizer; AMPK; AICAR
Received: November 22, 2018 Accepted: January 09, 2019 Published: January 22, 2019
Although radiotherapy is often used to treat localized disease and for palliative care in prostate cancer patients, novel methods are required to improve the sensitivity of aggressive disease to ionizing radiation. AMP-activated protein kinase (AMPK) is an energy sensor which regulates proliferation, aggressiveness and survival of cancer cells. We assessed the ability of the AMPK activator 5-aminoimidazole-4-carboxamide-1-β-D-ribofuranoside (AICAR) to sensitize prostate cancer cells to radiation. Prostate cancer cell lines LNCaP and PC3 were treated with X-rays and AICAR then assessed for clonogenic survival, spheroid growth delay, cell cycle progression, and AMPK and p53 activity. AICAR synergistically enhanced the clonogenic killing capacity, spheroid growth inhibition and pro-apoptotic effect of X-rays. The mechanism of radiosensitization appeared to involve cell cycle regulation, but not oxidative stress. Moreover, it was not dependent on p53 status. Treatment of PC3 cells with a fatty acid synthase inhibitor further enhanced clonogenic killing of the combination of X-rays and AICAR, whereas mTOR inhibition caused no additional enhancement. These results indicate that interference with metabolic signalling pathways which protect cells against irradiation have the potential to enhance radiotherapy. Activation of AMPK in combination with radiotherapy has the potential to target metabolically active and aggressive tumors which are currently untreatable.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.